InnoCan Pharma (OTC:INNPF) Stock, Quote.Headers.trade-ideas

Summit Hotel Properties

InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

cannabis, stock market, trading, earnings Business,Cannabis,Leaves,Marijuana,Stock,Exchange,Market,Or,Trading,Analysis

Cannabis

Earnings

News

INNPF

Innocan Pharma reports 174% YoY revenue growth in Q3 2024, driven by innovation in cannabinoids and strong sales from BI Sky Global Ltd.

Cannabinoid Leader Innocan Pharma&#39;s Q3: 174% YoY Revenue Growth

cannabis money, cannabis earnings, marjijuana money,

AMZN

CSE:INNO

INNO

Innocan Pharma&#39;s Q1 2024 revenue surged 334% to $6.8M, driven by strong sales growth from BI Sky Global. Read about financial performance.

CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark

Cannabis oil regulation(Shutterstock)(18)

Health Care

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA, for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the company initiated the regulatory process with the FDA for the approval of its prolonged CBD release technology for human use.

This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain

Summit Hotel Properties, Inc. 5.875% Series F Cumulative Redeemable Preferred Stock, $0.01 par value per share

Summit Hotel Properties Inc

INNOCAN PHARMA CORP. by Innocan Pharma Corp.

InnoCan Pharma Corp

Small Cap

Press Releases

Innocan Pharma Reports Third Quarter 2024 Financial Results

Innocan Pharma Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs

Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024

Innocan Pharma Announces Private Placement of Units

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60

FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025

Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone

Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis

Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest

Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited

InnoCan Pharma

Comments

InnoCan Pharma

InnoCan Pharma (OTC:INNPF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga